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Antimicrobial activity of Tigecycline against nosocomial
pathogens in Pakistan: A multicenter study
Altaf Ahmed,1 Afia Zafar,2 Sajjad Mirza3
Liaquat National Hospital,1 Aga Khan University Hospital,2 Karachi, Armed Forces Institute of Pathology,3 Rawalpindi.
Abstract
Objective: To measure the in-vitro activity of various antibiotics including tigecycline against Gram negative and
positive nosocomial aerobic isolates.
Methods: A total of 430 clinical isolates of both Gram positive (143) and negative (287) aerobic bacteria were
used from 3 centres during the year 2006 and 2007. Minimum inhibitory concentration (MIC) was determined
using broth micro dilution panels. Antibiotic resistance was interpreted using CLSI guidelines. 
Results: Most of the isolates were resistant to more than one drug. Resistance to tigecycline was not found.
Tigecycline (1ug/ml) had low MIC against organisms tested.
Conclusion: This data indicates that tigecycline, a new drug in its class, has broad-spectrum in-vitro activity
against both Gram negative and positive nosocomial isolates. Therefore, it may be a suitable drug to be used for
the treatment of highly resistant nosocomial infections (JPMA 59:240; 2009).
Introduction
Irrational use of antibiotics has resulted in the
emergence of resistant bacteria globally. In Pakistan, lack of
infection control practice and non existent formal antibiotic
policies has further augmented this problem. There have been
reports from all over the country on the rising trend of
nosocomial pathogens producing extended spectrum beta
lactamase (ESBL) and methicillin resistant Staphylococcus
aureus.1-4 Infections due to these organisms have resulted in
increased mortality, morbidity and cost of treatment.5
Tigecycline is a new injectable glycylcycline
antibacterial product. It inhibits protein translation in
bacteria by binding to the 30S ribosomal subunit and
blocking entry of amino-acyl tRNA molecules into the A
site of the ribosome. This prevents incorporation of amino
acid residues into elongating peptide chains resulting in
inhibition of protein synthesis.
This study was conducted to evaluate the in-vitro
activity of tigecycline against nosocomial pathogens
(aerobic) and compare its activity with other commonly used
antibiotics in our hospitals. 
Materials and Methods
Nosocomial isolates were tested at three different
hospital laboratories between 2006 and 2007. The
laboratories which participated were Liaquat National
Hospital Karachi, Aga Khan University Hospital Karachi and
Armed Forces Institute of Pathology, Rawalpindi. A total of
430 Clinical isolates of both Aerobic Gram positive (143) and
Gram negative (287) aerobic bacteria were included from all
types of specimens. Clinically significant isolates were
identified on the basis of Gram stain, morphology and
biochemical reactions. Final confirmation of isolates was also
performed by Laboratories International for microbiology
studies, a division of International Health Management
Associates, Inc, Schaumburg, IL, USA.
Minimum inhibitory concentrations (MICs) were
determined by the broth microdilution method of the
Clinical and Laboratory Standards Institute (CLSI) using
gram-negative broth panels (Microscan, Dade Behring,
Sacramento, CA, USA). All panels were incubated for 16-
20 hours aerobically at 350C as per CLSI guidelines.6
Quality control strains used were E.coli ATCC 25922,
Staphylococcus aureus ATCC 29213, E.faecalis ATCC
29212, S.pneumoniae ATCC 49619, and H.influenzae
ATCC 49247. These were all sensitive strains. They were
used with each batch as indicated.
Susceptibilities were determined according to the
interpretive criteria of CLSI.6 No interpretive criteria for
disc diffusion method have been approved for
tigecycline when testing Acinetobacter spp. E.coli and
K.pneumoniae were tested for ESBL production using
CLSI guidelines.
MICs and susceptibilities were determined against
amoxicillin-clavulanate, piperacillin-tazobactam, levofloxacin,
minocycline, ceftazidime, ceftriaxone, cefepime, imipenem,
amikacin, ampicillin and tigecycline. Tigecycline, ampicillin
and amoxicillin-clavulanate were not tested against
Acinetobacter spp., as no interpretive criteria were available for
disc diffusion methodology. Pseudomonas aeruginosa is not
reported in this study as it is intrinsically resistant to
tigecycline.
Results
Results of isolates tested by both disc diffusion method
and MICs are given.
Tigecycline showed no resistance by disc diffusion
method against all 360 isolates included in the study (Table
1). This included both Gram positive (Enterococcus spp.,
Staphylococc aureus and Streptococcus spp.) and negative
isolates (Enterobacter spp., Klebsiella pneumoniae.,
Serratia spp. and Eschericia coli). It also showed very low
MIC against all isolates including Acinetobacter spp. (Table
2). Acinetobacter spp. on the other hand had higher MICs
for all antibiotics including imipenem but for tigecycline
MIC was very low (1 ug/ml) (Table 3).
Discussion
We report uniform activity of tigecyline against
nosocomial Gram negative and positive organisms isolated in
three clinical microbiology laboratories affiliated with tertiary
care hospitals. We also report low MICs (1-2 ug/ml) of
tigecycline for isolates we tested. 
Antimicrobial resistance among Gram negative and
positive pathogens in Pakistan is on the rise. A number of
reports have been published showing presence of ESBL
producing E.coli and Klebsiella species in the community as
well as in hospitals. Recently Jabeen et al reported 40% of the
2840 isolates tested as ESBL producers. Among theses ESBL
positive isolates 50% were Enterobacter species, 41% E.coli
and 36% K. pneumoniae.1 In another study conducted in 1999
the frequency of ESBL producing enterobacteriacae was 35%.2
In a multicenter study Hafiz et al reported frequency of
isolation of MRSA as 42%.3
Prevalence of multiresistant Acinetobacter spp. is also
rising in intensive care units making treatment options much
more costly and difficult. In a recent study conducted in a
tertiary care hospital in Karachi, 65% isolates of Acinetobacter
species. obtained from blood isolates of febrile neutropenic
patients were resistant to imipenem.7 The emergence of
carbapenem resistance among Acinetobacter species is
alarming. In our study imipenem resistance in Acinetobacter
spp. was 63%. This study also shows high MIC 90 for several
antibiotics against Acinetobacter species. However tigecycline
showed low MICs of <2ug/ml for majority of the isolates
tested. This finding is in concordance with Diane et al.8 For
MRSA and for ESBL producing Enterobacteriaceae in-vitro
results of tigecycline are in full agreement with other studies
reported earlier.8,9 This drug was found uniformly active
against both groups of organisms with low MIC results. 
Tigecycline is the first of the glycylcyclines which has
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Table: 1 Susceptibility pattern of tigecycline against various
isolates by disc diffusion method (n=360).
Organisms Number % Susceptibility % Intermediate % Resistance
Enterobacter spp. 48 97.92 2.08 0
Enterococcus spp. 44 100 0 0
Eschericia coli 76 100 0 0
Klebsiella pneumoniae. 71 94.29 5.71 0
Staphylococcus aureus 69 100 0 0
Serratia spp. 23 90.91 9.09 0
Strep. pneumoniae. 30 100 0 0
Table: 2 MICs of tigecycline against various pathogens (n=430).
Organisms Number MICs ug/ml
Staphylococcus aureus 69 0.5
Acinetobacter spp. 41 1
Enterobacter spp. 48 1
E. coli 76 0.5
K. pneumoniae 71 2
Enterococcus spp. 44 0.25
Haemophilus spp. 29 0.5
Strept. pneumoniae 30 0.06
Serratia spp. 22 2
Table 3: MICs of Acinetobacter species (41) against various
antibiotics.
Acinetobacter species MICs ug/ml
Amikacin 128
Amoxicillin/clavulanic acid 64
Ampicillin 64
Cefepime 64
Ceftazidime 64
Ceftriaxone 128
Imipenem 32
Levofloxacin 16
Minocycline 4
Piperacillin/tazobactam 256
Tigecycline 1
been marketed recently. It has remained unaffected by bacterial
resistance due to a number of defense mechanisms such as
protein binding, beta-lactamase production (ESBL production,
AmpC hyperproducers), DNA gyrase alterations, the van
resistance genes, plus other mechanisms that are used by many
of the commonly encountered isolates in community-acquired
and nosocomial infections.10-12
A study published by Jabeen et al1 reported that in
enterobacteriaceae resistance to non-beta lactam antibiotics
(fluoroquinolones, aminoglycosides and co-trimoxazole) was
more frequent in ESBL producing organisms (p<0.05) than in
non ESBL producers. Cross resistance to amikacin,
gentamicin, co-trimoxazole and ofloxacin was 14%, 51%,
22%, 41% among ESBL producers than non-ESBL isolates. In
this study none of the ESBL producing organisms were found
resistant to imipenem, similar to our study. Authors were not
able to check tigecycline as it was not available in 2005. This
study showed lowest MIC for imipenem and tigecycline
against Enterobacter species and K. pneumoniae and the same
result was found against E.coli followed by amikacin. 
ESBL producing K.pneumoniae did not show higher
MICs for imipenem and tigecycline. However in USA a large
scale study conducted found higher MICs against imipenem.
(MIC 90 16ug/ml).11
Finally, it is concluded that tigecycline is not yet
affected by various resistance mechanisms affecting other
antibiotics since that requires research at a molecular level. It
has broad spectrum activity against both Gram negative and
positive nosocomial isolates. Therefore we suggest that in the
current situation it can be a suitable drug for the treatment of
highly resistant nosocomial infections and it should not be used
for empirical treatment. For future, we recommend that to deal
with the ever-increasing antimicrobial resistance, it is
necessary to monitor resistance patterns carefully and
continuously.
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